Monopar Therapeutics Inc. (MNPR)
$117.57
$5.64
(5.04%)
As on 01-Sep-2026 16:00EDT
Market cap
$751 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
5.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.3
-
Face value
--
-
Shares outstanding
6,712,172
9 Years Aggregate
CFO
$-37.43 Mln
EBITDA
$-60.37 Mln
Net Profit
$-59.98 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
| 80.0 | 8.5 | 80.8 | 244.3 | 231.4 | 35.4 | -- |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
| 196.8 | 1,167.4 | -85.7 | -26.2 | -47.5 | -63.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
117.6 | 751.0 | 0.0 | -17.8 | -- | -13.3 | -- | 5.9 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 260.3 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 71.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.9 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 363.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.2 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Monopar Therapeutics (MNPR)
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine;... MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Read more
-
Co-Founder, CEO, President & Director
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
-
Co-Founder, CEO, President & Director
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
-
Headquarters
Wilmette, IL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Monopar Therapeutics (MNPR)
What is the current share price of Monopar Therapeutics Inc (MNPR) Today?
The share price of Monopar Therapeutics Inc (MNPR) is $117.57 (NASDAQ) as of 01-Sep-2026 16:00 EDT. Monopar Therapeutics Inc (MNPR) has given a return of 231.41% in the last 3 years.
What is the current PB & PE ratio of Monopar Therapeutics Inc (MNPR)?
Since, TTM earnings of Monopar Therapeutics Inc (MNPR) is negative, P/E ratio is not available.
The P/B ratio of Monopar Therapeutics Inc (MNPR) is 5.85 times as on 28-Aug-2026, a 13 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-31.86 |
3.17 |
2024 |
-16.21 |
4.59 |
2023 |
-0.60 |
0.91 |
2022 |
-2.92 |
3.04 |
2021 |
-4.45 |
2.13 |
What is the 52 Week High and Low of Monopar Therapeutics Inc (MNPR)?
The 52-week high and low of Monopar Therapeutics Inc (MNPR) are Rs 124.42 and Rs 32.77 as of 02-Sep-2026.
What is the market cap of Monopar Therapeutics Inc (MNPR)?
Monopar Therapeutics Inc (MNPR) has a market capitalisation of $ 751 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Monopar Therapeutics Inc (MNPR)?
Before investing in Monopar Therapeutics Inc (MNPR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.